- Home
- Media Center
- Press releases
- Innovative Medicine
Innovative Medicine
Janssen and Johnson & Johnson Innovation Launch Next-Gen Baby Box QuickFire Challenge in Collaboration with Sitra, Tekes and VTT
Challenge seeks ideas and solutions to celebrate 80th anniversary of Finnish Baby Box and spur innovation to promote child health and healthy parenting
Janssen Announces Submissions in Europe and US for Single- Tablet Regimen of Dolutegravir plus Rilpivirine - the First Two-Drug HIV Maintenance Treatment
- Two-drug regimen could offer many patients the option to switch to a regimen that does not include a nucleotide reverse transcriptase inhibitor -
Janssen Enters Into Worldwide Exclusive License and Collaboration Agreement With Protagonist Therapeutics, Inc. For The Oral Interlukin-23 Receptor Antagonist Drug Candidate For The Treatment of Inflammatory Bowel Disease
Long-standing relationship between Johnson & Johnson Innovation, Janssen and Protagonist Therapeutics leads to advancement of promising oral drug candidate for Crohn’s disease and ulcerative colitis
Real-World Evidence Shows Oral INVOKANA® 300 mg Demonstrates Comparable A1C Reduction and Control to Injectable GLP-1 Receptor Agonists
Patients Taking INVOKANA® 300 mg Were Significantly Less Likely to Discontinue the Medication or Be Prescribed a New Antihyperglycemic Agent
Janssen Research & Development Submits Supplemental New Drug Application to U.S. FDA Based on EINSTEIN CHOICE Data, Which Showed Superiority with XARELTO® (rivaroxaban) Versus Aspirin in Reducing Risk of Recurrent Venous Thromboembolism (VTE), with Low Rates of Major Bleeding Across Groups
Filing seeks update to prescribing information to include additional dosage of XARELTO® to reduce risk of recurrent VTE
European Commission Extends Approval for Janssen’s DARZALEX®▼(daratumumab) to Include Multiple Myeloma Patients Who Have Received at Least One Prior Therapy
First-in-class CD38-directed monoclonal antibody now approved for use in combination with two standard of care regimens